ReviewJournal of the Endocrine Society2025
Effect of Vitamin D on Regression to Normal Glucose Regulation in Adults With Prediabetes.
Review in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The 2024 Endocrine Society Guideline on Vitamin D: Comprehensive Summary and Critical Appraisal.Nutrients · 2026Pooled it
- Dysglycemia and Cardiometabolic Risk: Pathophysiological Rationale and the Emerging Role of Nutraceuticals in Integrated Prevention.Nutrients · 2026Review
- Protecting Citizens, Enabling Prevention: A Framework for Responsible Dietary Supplement Use in Europe.Nutrients · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Meta-analyses of clinical trials have shown that vitamin D lowers the risk of progression from prediabetes to diabetes. Less is known about whether vitamin D promotes regression to normal glucose regulation (NGR). We conducted a systematic review and meta-analysis of clinical trials with vitamin D in adults with prediabetes that have reported on the outcome of regression to NGR. We searched Medline (through PubMed), Embase, and the trial registry ClinicalTrials.gov from inception to July 3, 2024, for randomized, controlled trials of at least 6 months' duration that reported on the effects of oral vitamin D supplementation on NGR in adults with prediabetes. The search identified 10 eligible trials, involving 4478 participants. The baseline characteristics of the study cohorts were: mean age range 20 to 74 years, mean body mass index range 24 to 38, mean blood 25-hydroxyvitamin D range 12 to 28 ng/mL. The median study duration range was 0.5 to 5 years. Across trials, 416 of 2253 (18.5%) participants randomly assigned to vitamin D reached NGR vs 312 of 2225 (14.0%) participants randomly assigned to placebo. In all trials, the relative risk of regression to NGR favored the vitamin D group, ranging from 1.09 to 12.6. After combining data, the summary relative risk of regression to NGR for vitamin D vs placebo was 1.27 (95% CI, 1.12-1.45), with no heterogeneity (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.